Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells

Journal of Experimental Medicine

Volumn 198, Issue 4, 2003, Pages 569-580

  Overwijk, Willem W ^a,b   Theoret, Marc R ^c   Finkelstein, Steven E ^a   Surman, Deborah R ^a   De Jong, Laurina A ^b   Vyth Dreese, Florry A ^b   Dellemijn, Trees A ^b   Antony, Paul A ^a   Spiess, Paul J ^a   Palmer, Douglas C ^a   Heimann, David M ^a   Klebanoff, Christopher A ^c   Yu, Zhiya ^a   Hwang, Leroy N ^a   Feigenbaum, Lionel ^d   Kruisbeek, Ada M ^b   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

Adoptive cell transfer; IL 2; Immunotherapy; Recombinant poxvirus; T cell epitope

Indexed keywords

CANCER VACCINE; CYTOKINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 2; SYNTHETIC PEPTIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; EMBRYO; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LETHALITY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION; VACCINATION; VIRUS RECOMBINANT; VITILIGO;

ADOPTIVE TRANSFER; ANIMALS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; INTERFERON TYPE II; INTERLEUKIN-2; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; SELF TOLERANCE; SURVIVAL RATE; VACCINATION;

EID: 0041419656     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030590     Document Type: Article

References (51)

1. Houghton, A.N., J.S. Gold, and N.E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134-140.
2. Weber, L.W., W.B. Bowne, J.D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J.J. Lewis, and A.N. Houghton. 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102:1258-1264.
3. Pardoll, D.M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227-238.
4. Rosenberg, S.A. 2001. Progress in human tumour immunology and immunotherapy. Nature. 411:380-384.
5. Overwijk, W.W., D.S. Lee, D.R. Surman, K.K. Irvine, C.E. Touloukian, C.C. Chan, M.W. Carroll, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1999. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA. 96:2982-2987.
6. Overwijk, W.W., and N.P. Restifo. 2000. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other." Crit. Rev. Immunol. 20:433-450.
7. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219-230.
8. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
9. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
10. Nguyen, L.T., A.R. Elford, K. Murakami, K.M. Garza, S.P. Schoenberger, B. Odermatt, D.E. Speiser, and P.S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:423-435.
11. Touloukian, C.E., W.W. Leitner, R.E. Schnur, P.F. Robbins, Y. Li, S. Southwood, A. Sette, S.A. Rosenberg, and N.P. Restifo. 2003. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/ tumor melanoma antigen, OA1. J. Immunol. 170:1579-1585.
12. Touloukian, C.E., W.W. Leitner, P.F. Robbins, Y.F. Li, X. Kang, R. Lapointe, P. Hwu, S.A. Rosenberg, and N.P. Restifo. 2002. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 62:5144-5147.
13. Speiser, D.E., R. Miranda, A. Zakarian, M.F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R.M. Zinkernagel, and P.S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
14. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA. 95:1178-1183.
15. Spiotto, M.T., P. Yu, D.A. Rowley, M.I. Nishimura, S.C. Meredith, T.F. Gajewski, Y.X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
16. Wang, M., V. Bronte, P.W. Chen, L. Gritz, D. Panicali, S.A. Rosenberg, and N.P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685-4692.
17. Ochsenbein, A.F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:1058-1064.
18. Tham, E.L., P. Shrikant, and M.F. Mescher. 2002. Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J. Immunol. 168:1190-1197.
19. Hanson, H.L., D.L. Donermeyer, H. Ikeda, J.M. White, V. Shankaran, L.J. Old, H. Shiku, R.D. Schreiber, and P.M. Allen. 2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13:265-276.
20. Wick, M., P. Dubey, H. Koeppen, C.T. Siegel, P.E. Fields, L. Chen, J.A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
21. Melief, C.J., S.H. Van Der Burg, R.E. Toes, F. Ossendorp, and R. Offringa. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188:177-182.
22. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
23. Seliger, B., U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber. 2001. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61:1095-1099.
24. Kawakami, Y., N. Dang, X. Wang, J. Tupesis, P.F. Robbins, R.F. Wang, J.R. Wunderlich, J.R. Yannelli, and S.A. Rosenberg. 2000. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23:17-27.
25. Sarma, S., Y. Guo, Y. Guilloux, C. Lee, X.F. Bai, and Y. Liu. 1999. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J. Exp. Med. 189:811-820.
26. Colella, T.A., T.N. Bullock, L.B. Russell, D.W. Mullins, W.W. Overwijk, C.J. Luckey, R.A. Pierce, N.P. Restifo, and V.H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen. Implications for tumor immunotherapy. J. Exp. Med. 191:1221-1232.
27. Van Parijs, L., and A.K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:243-248.
28. Irvine, K.R., M.R. Parkhurst, E.P. Shulman, J.P. Tupesis, M. Custer, C.E. Touloukian, P.F. Robbins, A.G. Yafal, P. Greenhalgh, R.P. Sutmuller, et al. 1999. Recombinant virus vaccination against "self' antigens using anchor-fixed immunogens. Cancer Res. 59:2536-2540.
29. Slansky, J.E., F.M. Rattis, L.F. Boyd, T. Fahmy, E.M. Jaffee, J.P. Schneck, D.H. Margulies, and D.M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 13:529-538.
30. Dyall, R., W.B. Bowne, L.W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J.J. Lewis, A.N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553-1561.
31. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
32. Zhai, Y., J.C. Yang, P. Spiess, M.I. Nishimura, W.W. Overwijk, B. Roberts, N.P. Restifo, and S.A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20:15-25.
33. Kouskoff, V., K. Signorelli, C. Benoist, and D. Mathis. 1995. Cassette vectors directing expression of T cell receptor genes in transgenic mice. J. Immunol. Methods. 180:273-280.
34. Overwijk, W.W., D.R. Surman, K. Tsung, and N.P. Restifo. 1997. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 12:117-123.
35. Earl, P.L., N. Cooper, and B. Moss. 1991. Preparation of cell cultures and vaccinia virus stocks. In Current Protocols in Molecular Biology. F.M. Asubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, and L.A. Smith, editors. Greene Publishing Associates and Wiley Interscience, New York. 16.16.1-16.16.17.
36. Vyth-Dreese, F.A., H. Boot, T.A. Dellemijn, D.M. Majoor, L.C. Oomen, J.D. Laman, M. Van Meurs, R.A. De Weger, and D. De Jong. 1998. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology. 94:580-586.
37. Sotomayor, E.M., I. Borrello, E. Tubb, F.M. Rattis, H. Bien, Z. Lu, S. Fein, S. Schoenberger, and H.I. Levitsky. 1999. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5:780-787.
38. Bronte, V., K. Tsung, J.B. Rao, P.W. Chen, M. Wang, S.A. Rosenberg, and N.P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282-5292.
39. Tamura, Y., P. Peng, K. Liu, M. Daou, and P.K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:117-120.
40. Kannan, K., N.E. Sharpless, J. Xu, R.C. O'Hagan, M. Bosenberg, and L. Chin. 2003. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc. Natl. Acad. Sci. USA. 100:1221-1225.
41. Noonan, F.P., J.A. Recio, H. Takayama, P. Duray, M.R. Anver, W.L. Rush, E.C. De Fabo, and G. Merlino. 2001. Neonatal sunburn and melanoma in mice. Nature. 413:271-272.
42. Lee, P.P., C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
43. Gold, J.S., C.R. Ferrone, J.A. Guevara-Patino, W.G. Hawkins, R. Dyall, M.E. Engelhorn, J.D. Wolchok, J.J. Lewis, and A.N. Houghton. 2003. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170:5188-5194.
44. Wherry, E.J., J.N. Blattman, K. Murali-Krishna, M.R. van der, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
45. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
46. Kjaergaard, J., L. Peng, P.A. Cohen, J.A. Drazba, A.D. Weinberg, and S. Shu. 2001. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167:6669-6677.
47. Overwijk, W.W., M.R. Theoret, and N.P. Restifo. 2000. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6:S76-S80.
48. Blattman, J.N., J.M. Grayson, E.J. Wherry, S.M. Kaech, K.A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-547.
49. Trcka, J., Y. Moroi, R.A. Clynes, S.M. Goldberg, A. Bergtold, M.A. Perales, M. Ma, C.R. Ferrone, M.C. Carroll, J.V. Ravetch, and A.N. Houghton. 2002. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity. 16:861-868.
50. Bowne, W.B., R. Srinivasan, J.D. Wolchok, W.G. Hawkins, N.E. Blachere, R. Dyall, J.J. Lewis, and A.N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717-1722.
51. Rosenberg, S.A., and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81-84.